Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial

19 Jul, 2021

Authors: Compagnucci A , Chan M , Saïdi Y , Cressey T , Bamford A , Riault Y , Coelho A , Nolan A ,Chalermpantmetagul S , Amuge P , Musiime V , Violari A , Cotton M , Kekitiinwa A , Kaudha E , Groenewald M, Liberty A , Kanjanavanit S , Volokha A , Bologna R , Muñoz Hernández R , Fortuny-Guasch C , Paioni P , Marques L , Reliquet V , Welch S , Ford D , Giaquinto C , Gibb D , Babiker A , Ramos Amador J and The SMILE-PENTA17-ANRS 152 Trial Group

Published in: International Workshop of HIV Pediatrics 2021



– Children start ART very early and for life – Can we reduce number of drugs (sparing NRTIs)?
– Drugs with high genetic barrier to resistance are available for children

Overall Aim: To evaluate antiviral efficacy and safety of once daily INSTI+DRV/r compared to current SOC therapy in HIV-1 infected, virologically suppressed paediatric participants

Hypothesis: Children with chronic HIV infection on ART with suppressed viral load will maintain similar levels of suppression with once daily INSTI + darunavir/r compared to continued standard of care triple ART

View presentation slides